Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Tracing the origins of our political beliefs

What makes some people more vulnerable to extremism than others? How do we build cognitive resilience against extreme ideologies? And how does the brain react to misinformation on social media? These are some of the key political questions that political neuroscientist Leor Zmigrod [2016] is exploring, putting the science into our understanding of radicalisation.   Leor […]

A leading woman in STEAM

A Gates Cambridge Scholar has been selected as one of the 75 leading women in Science, Technology, Engineering, Arts and Mathematics in India. Yama Dixit will feature in the second edition of the book She Is, published by the Red Dot Foundation in partnership with the Office of the Principal Scientific Adviser, Government of India to mark 75 […]

Tackling the obesity epidemic in Africa

When she left school, Paula-Peace James-Okoro [2022] intended to become a medical doctor, but after starting a degree in Biochemistry she discovered a passion for the subject and for using it to address one of the major health challenges facing Africa – obesity. She says: “In Africa, the rates of metabolic diseases, like obesity and […]

Triple win for Bill Gates Sr. Prize

For the first time three Gates Cambridge Scholars are sharing this year’s Bill Gates Sr. Prize in recognition of their outstanding research and social leadership. Kim van Daalen, Reetika Subramanian and Cynthia Okoye have been selected for the prize which was established by the Gates Cambridge Trustees in June 2012 in recognition of the late […]